Tag: Dr. Jeffrey Weber,HD-IL2 therapy,Press Releases,SITC,cancer immunotherapy,choosing the right immunotherapy,deep learning,immunotherapy,machine learning,melanoma,overfitting
-
Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC
Blood-Based Assays to Predict Patient Response to Combination Checkpoint Blockade, High-dose interleukin 2 (HDIL-2) in Melanoma November 15, Boulder, CO…Studies presented by Biodesix® at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrated the potential for the utility of the company’s proprietary Diagnostic Cortex™ platform to design blood-based tests that provide…